Search

Your search keyword '"BENHAMOUDA, N."' showing total 134 results
Start Over Author "BENHAMOUDA, N."
134 results on '"BENHAMOUDA, N."'

6. P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer

Author

Benhamouda, N, primary, Sam, I, additional, Epaillard, N, additional, Gey, A, additional, Saldmann, A, additional, Pineau, J, additional, Hasan, M, additional, Verkarre, V, additional, Libri, V, additional, Mella, S, additional, Granier, C, additional, Broudin, C, additional, Ravel, P, additional, Jabla, B, additional, Chaput, N, additional, Albiges, L, additional, Vano, Y, additional, Adotevi, O, additional, Oudard, S, additional, and Tartour, E, additional

Published
2021
Full Text
View/download PDF

10. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Author

SIRIMA, S. B., Richert, Laura, Chene, A., KONATE, A. T., CAMPION, Cecilia, Dechavanne, S., SEMBLAT, J. P., BENHAMOUDA, N., BAHUAUD, M., Loulergue, P., NEBIE, I., Kabore, M., KARGOUGOU, D., Barry, A., OUATTARA, S. M., BOILET, Valerie, Allais, Florence, Roguet, G., HAVELANGE, N., LOPEZ-PEREZ, E., KUPPERS, A., KONATE, E., Roussillon, Caroline, KANTE, Myriam, BELARBI, L., DIARRA, A., Henry, N., SOULAMA, I., Ouedraogo, A., Esperou, H., Leroy, O., Batteux, F., TARTOUR, E., VIEBIG, N. K., THIEBAUT, Rodolphe, Launay, O., Gamain, B., Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Epidémiologie et Biostatistique [Bordeaux], and Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
parasitic diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, SISTM
Abstract

International audience; BackgroundPRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.MethodsThis first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18–35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253.FindingsBetween April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8–18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7–3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8–636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36–13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19–1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08–1·34).InterpretationPRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants.FundingBundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.

Published
2020
Full Text
View/download PDF

11. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

Author

Sirima, S.B., primary, Durier, C., additional, Kara, L., additional, Houard, S., additional, Gansane, A., additional, Loulergue, P., additional, Bahuaud, M., additional, Benhamouda, N., additional, Nebié, I., additional, Faber, B., additional, Remarque, E., additional, Launay, O., additional, Ouedraogo, E., additional, Sanou, G., additional, Gueguen, S., additional, Lopez Perez, E., additional, Ammour, K., additional, Kocken, C., additional, Batteux, F., additional, and Tartour, E., additional

Published
2017
Full Text
View/download PDF

14. PD-1 infiltrating T cells : a good prognostic biomarker in HPV associated head and neck cancer

Author

Badoual, Cécile, Hans, Stéphane, Merillon, N, Van Ryswick, C, Ravel, P, Benhamouda, N, Levionnois, E, Nizard, M, Si Mohamed, A, Besnier, N, Rotem-Yehudar, R, Pere, H, Tran, T, Chauvat, A, Dransart, E, Barry, B, Sandoval, F, Quintin-Colonna, F, Bruneval, P, Fridman, WH, Lemoine, FM, Oudard, S, Johannes, L, Olive, D, Brasnu, Daniel, Tartour, E, Service d'anatomo-pathologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 (LPP), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique (CNRS), Service d'oto-rhino-laryngologie et chirurgie cervico-faciale [CHU HEGP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Cytokines et Immunologie des Tumeurs Humaines (U753), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP ), LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 ( LPP ), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique ( CNRS ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Cytokines et Immunologie des Tumeurs Humaines ( U753 ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PD-1 infiltrating T cells, [ SHS.LANGUE ] Humanities and Social Sciences/Linguistics, [SHS.LANGUE]Humanities and Social Sciences/Linguistics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2013

15. High Reproducibility of ELISPOT Counts from Nine Different Laboratories.

Author

Sundararaman, S, Karulin, AY, Ansari, T, BenHamouda, N, Gottwein, J, Laxmanan, S, Levine, SM, Loffredo, JT, McArdle, S, Neudoerfl, C, Roen, D, Silina, K, Welch, M, Lehmann, PV, Sundararaman, S, Karulin, AY, Ansari, T, BenHamouda, N, Gottwein, J, Laxmanan, S, Levine, SM, Loffredo, JT, McArdle, S, Neudoerfl, C, Roen, D, Silina, K, Welch, M, and Lehmann, PV

Published
2015

17. 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC)

Author

Oudard, S., primary, Benhamouda, N., additional, Escudier, B., additional, Ravel, P., additional, Kothari, D., additional, Mehmud, F., additional, Levionnois, E., additional, Sevin, E., additional, Negrier, S., additional, Barthelemy, P., additional, Berdah, J.F., additional, Ravaud, A., additional, Sternberg, C.N., additional, Bono, P., additional, Porta, C., additional, Giorgi, U. De, additional, Parikh, O., additional, Hawkins, R., additional, Highley, M., additional, Tartour, E., additional, Decker, T., additional, and Wilkie, J., additional

Published
2015
Full Text
View/download PDF

24. Thermal properties of the Tin odd isotopes Sn.

Author

Kadi, H. and Benhamouda, N.

Subjects
*TIN isotopes, *THERMAL properties of metals, *QUASIPARTICLES, *ENTROPY, *FLUCTUATIONS (Physics)
Abstract

We propose to study the thermal properties of the odd isotopes of Tin: Sn. To this end, one used two methods to evaluate the properties of these elements. The first theoretical consideration uses a simple prescription to perform the calculation of these properties based on those of even-even neighboring isotopes, assuming the quasi-particle entropy extensivity. The even-even elements are treated as part of the Modified Lipkin-Nogami (MLN) method that allows to take into account the quantal and statistical fluctuations. The second theoretical approach consists of the generalization of the MLN formalism in the case of odd systems, by using the blocking technique. Then, this approach is applied to evaluate the thermal properties of the considered elements. The obtained results by both theoretical approaches are compared to the experimental data. The latter are deduced from the experimental level density within the canonical ensemble. It appears that the assumption of quasi-particle entropy extensivity at low excitation energy allows a simple and an effective treatment of thermal properties of odd nuclei. Indeed, this approach allows to give a good reproduction of experimental data in the particular in the region where the pairing transition occurs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

42. Pairing phase transition in 106,107,108Pd.

Author

Kadi, H. and Benhamouda, N.

Subjects
*PHASE transitions, *LEAD isotopes, *FLUCTUATIONS (Physics), *HEAT capacity, *THERMAL properties, *SUPERFLUIDITY
Abstract

The pairing phase transition is investigated in hot even-even and even-odd Pd isotopes such as 106 ≤ A ≤ 108 in a framework of a microscopic approach that takes into account the statistical fluctuations. In this aim, one considers the Modified BCS method (MBCS). The latter is extended to the odd system case, where the blocking effect is included. The model was applied to the evaluation of the thermal properties such as the excitation energy, entropy and heat capacity. The obtained results are compared on one hand to the usual finite temperature BCS (FTBCS) method and on the other hand to the experimental data. The obtained results allow to show that the thermal fluctuations smooth out the superfluid-normal (SN) phase transition observed in the usual FTBCS results. Moreover, in the region where the pairing phase transition occurs, the experimental data of thermal properties are better reproduced when statistical fluctuations are considered in MBCS method instead of the FTBCS approach. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

46. Effects of the particle-number projection on the isovector pairing energy.

Author

Fülöp, Zsolt, Gyürky, György, Somorjai, Endre, Allal, N. H., Fellah, M., Oudih, M. R., and Benhamouda, N.

Abstract

The usual neutron-proton BCS wave function is simultaneously projected on both the good neutron and proton numbers using a discrete projection operator. The projected energy of the system is deduced as a limit of rapidly convergent sequence. It is numerically studied for the N=Z nuclei of which "experimental" pairing gaps may be deduced from the experimental odd-even mass differences. It then appears that the particle-number fluctuation effect is even more important than in the case of pairing between like-particles. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

49. MICROSCOPIC ANALYSIS OF SHAPE EVOLUTION IN ISOTOPES.

Author

OUDIH, M. R., FELLAH, M., ALLAL, N. H., and BENHAMOUDA, N.

Subjects
POTENTIAL energy surfaces, GROUND state (Quantum mechanics), MICROSCOPY, DENSITY functional theory, PARTICLES (Nuclear physics), SYMMETRY (Physics)
Abstract

The shape evolution of even-even isotopes from the line of stability up to the two-neutron drip-line is investigated within the self-consistent Hartree-Fock-Bogoliubov theory in both the axial and triaxial symmetries. The Skyrme energy density functional SLy4 has been considered in the particle-hole channel, while the zero range delta-interaction has been employed in the particle-particle channel. In order to correctly treat the pairing correlations, a particle-number projection was carried out by the Lipkin-Nogami (LN) method. The two-neutron separation energies and root-mean-square (rms) charge radii are investigated and compared with available experimental data. The evolution of the potential energy surfaces in the (β, γ) deformation plane is presented and discussed. In addition, the obtained ground state deformation parameters are compared to those obtained by other models. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

50. EFFECT OF THE STATISTICAL FLUCTUATIONS IN THE PAIRING TRANSITION IN THE CASE OF 166Er.

Author

KADI, H., BENHAMOUDA, N., and HADDOUCHE, A.

Subjects
*FLUCTUATIONS (Physics), *STATISTICS, *PHASE transitions, *HEAT capacity, *SUPERFLUIDITY, *PREDICTION models, *QUASIPARTICLES
Abstract

The S-shaped heat capacity, which has recently been claimed to be a fingerprint of the superfluid-to-normal phase transition in nuclei, is studied in the case of 166 element. The calculations are performed by means of the modified Bardeen-Cooper-Schrieffer (MBCS) approach that takes into account the thermal fluctuation. The obtained results are compared to the experimental data and to the FT-BCS theoretical predictions. The present study illustrates the effect of the fluctuations of the quasiparticle (QP) number on the heat capacity. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results